GlassScriptPhysician profile
Vlad Prelipcean
NPI 1033188966
$7,150.70
in general payments reported to CMS, 2019-2025
36 companies · $899 in 2025
The $899 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $1,555 · 2021: $1,448 · 2022: $1,114 · 2023: $572 · 2024: $789 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $856.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $744.24 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.60 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $578.36 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $566.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $518.00 | 2020-2022 | |
| Glaxosmithkline, LLC. | $344.31 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $329.97 | 2021-2025 | |
| Lilly USA, LLC | $266.51 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.37 | 2019-2025 | Relistor, Xifaxan |
| Exact Sciences Corporation | $257.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $249.26 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.90 | 2025 | |
| Sanofi-Aventis U.S. LLC | $130.84 | 2020 | |
| Abbott Laboratories | $125.87 | 2024 | Freestyle Libre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.48 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $103.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $103.07 | 2019-2024 | Capvaxive |
| Allergan, INC. | $78.07 | 2019-2020 | |
| Esperion Therapeutics, INC. | $69.71 | 2020-2022 | |
| Dexcom, INC. | $67.36 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $60.43 | 2019-2023 | |
| Antares Pharma, INC. | $58.15 | 2024 | Xyosted |
| Avanir Pharmaceuticals, INC. | $49.61 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $49.52 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $47.22 | 2022-2023 | Quviviq |
| Biogen, INC. | $43.19 | 2020-2021 | |
| Shield Therapeutics INC | $37.22 | 2023-2024 | Accrufer |
| Arbor Pharmaceuticals, INC. | $34.59 | 2020 | |
| Eisai INC. | $31.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.48 | 2021-2024 | Eliquis |
| Genentech USA, INC. | $22.18 | 2020 | |
| Boston Scientific Corporation | $16.29 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.76 | 2023 | Horizant |
| Emmaus Medical, INC. | $14.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vlad Prelipcean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.